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of some of the components of 
outbreak control in stopping the 
spread of HIV is unproven. Whereas 
epidemiological surveillance for HIV 
is probably more advanced than for 
most other public health problems 
in low-income and middle-income 
countries, and has been an important 
technique in programme planning and 
implementation, traditional contact 
tracing has indeed been used less in 
most democratic countries, and there 
is no evidence that it has contributed 
to limiting the spread of HIV. Most 
countries are now emphasising broad 
access to HIV testing, counselling, 
and education, and informing the 
partners of those found HIV positive. 
Conﬁ dentiality, not secrecy, is a 
general ethical obligation in medical 
practice, although speciﬁ c exceptions 
are accepted in most societies.
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Role of the UK Biobank 
Ethics and Governance 
Council
In their Comment (Sept 12, p 861),1 
David Jones and Calum McKellar 
misunderstand the role of the UK 
Biobank Ethics and Governance 
Council (EGC). The EGC is an 
independent body set up to advise 
and monitor UK Biobank; it is not a 
creation of UK Biobank. The EGC does 
not decide on uses of UK Biobank, 
as suggested by Jones and McKellar, 
but rather recommends action as the 
project develops.
The Council’s role is to safeguard 
participants’ interests now and in 
the future because it is the long-
term nature of the project that brings 
most challenges. No one can predict 
which applications might be made, 
and participants agree to take part on 
this understanding. The EGC advises 
UK Biobank on keeping participants 
informed and will advise on 
applications as and when they arise. 
The UK Biobank Ethics and 
Governance Framework2 explicitly 
states that: “Further consent will be 
sought for any proposed activities 
that do not fall within the existing 
consent.” This is not a trivial matter. 
It depends on what is proposed 
scientiﬁ cally, expectations of 
participants, and social mores at 
the time of an application. It is the 
responsibility of the EGC to advise on 
such circumstances.
The proposition put by Jones and 
McKellar on somatic cell nuclear 
transfers was hypothetical and the 
Council took the view that it is not its 
role to second guess science or social 
attitudes at an as-yet-undetermined 
time.
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Access to pain treatment 
a luxury for most
Guy Micco and colleagues (Sept 12, 
p 872)1 are right to emphasise that, 
whenever possible, patients near 
the end of their lives must be free to 
choose whether their care includes 
optimum pain relief, or more limited 
use of opioids with the aim of pro-
mot ing consciousness and lucidity. 
However, for most patients worldwide, 
there is no such choice.
WHO estimates that each year 
5·5 million patients with terminal 
cancer and 1 million with end-stage 
HIV/AIDS die without access to 
adequate pain treatment.2 According 
to Sevil Atasoy, President of the 
International Narcotics Control Board, 
access to morphine is “virtually non-
existent in 150 countries”.3
When Human Rights Watch 
spoke to people who had lived with 
untreated severe pain,4 they expressed 
sentiments similar to those of torture 
survivors: all they wanted was for 
the pain to stop. Several people told 
us that they had wanted to commit 
suicide, had told doctors or friends that 
they wanted to die, or had prayed for 
death. We found that barriers to pain 
treatment access included inadequate 
education for health professionals, 
doctors’ fear of prescribing opioid 
medications, inadequate supply and 
distribution systems, and unnecessarily 
restrictive regulation—for example, in 
Ukraine three doctors must sign any 
opioid prescription. Many of these 
barriers could be removed through 
cost-neutral or low-cost reforms.4
The desire to die with dignity, 
according to one’s own concept 
of a “good” death, is universal. 
Governments should work to ensure 
access to pain treatment, not as a 
luxury of the wealthiest nations, but in 
realisation of a universal human right.
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